X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Surufatinib,Tislelizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
Details:
This trial is to explore potential synergistic activity of the novel, oral angio-immuno kinase inhibitor surufatinib with the anti-PD-1 antibody tislelizumab in enhancing overall antitumor activity from inhibition of angiogenesis along with stimulation of an immune response.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Savolitinib,Osimertinib
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: GL Mountrose Investment Two
Deal Size: $169.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 24, 2021
Details:
China MediTech Limited will sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated OTC drug joint venture business which includes Osimertinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Details:
final analysis of savolitinib in Phase Ib TATTON study Parts B and D will be presented at the upcoming virtual 2020 World Conference on Lung Cancer (WCLC 2020).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Savolitinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
New and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming ASCO20 Virtual Scientific Program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Surufatinib,Toripalimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2020
Details:
The presentation will highlight data from a Phase I trial of surufatinib plus toripalimab in patients with advanced solid tumors.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
